Decheng Capital
Finance · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
375 Park Ave Ste 3707, New York City, Ne...Phone Number
(650) 233-0688Website
www.decheng.comRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
2
1
2
2
About Decheng Capital
Decheng Capital is a global investment firm established in 2012, specializing in providing capital and strategic support to early-stage life science companies and growth stage healthcare companies. With over $2.1 billion in capital, the firm aims to build legendary companies by leveraging revolutionary technologies and strong market presence. Decheng Capital partners with entrepreneurs, world-class scientists, and strategic partners to create value in the rapidly growing healthcare industry. The firm is headquartered in Silicon Valley, with additional locations in Shanghai and New York.Explore more
Decheng Capital Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Decheng Capital your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Decheng Capital has new funding data
Website visits: Recent activity has been detected on your website
Decheng Capital, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Decheng Capital recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Decheng Capital
Product Launch: Get notified when Decheng Capital launches new products
Check out if Decheng Capital is spiking on competitors!
Click to see if Decheng Capital had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Decheng Capital has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Decheng Capital
Find 3 more new buyers
Compare Similar Companies to Decheng Capital
Compare insights from companies similar to Decheng Capital, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Decheng Capital is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Decheng Capital is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Decheng Capital.
Decheng Capital Tech Stack
A closer look at the technologies used by Decheng Capital
Most Recent Scoops
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Decheng Capital News & Media
Firefly Bio Debuts With $94 Million Series A Financing
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company. Firefly has developed a novel platform to treat cancer using degrader antibody conjugates (DACs). DACs represent the convergence of two technologies – antibody drug conjugates (ADCs) and protein degraders. Despite the power of eachGrit Biotechnology Closes $60M Series B Financing
Grit Biotechnology, a Shanghai, China-based cell therapy company, raised $60M in Series B funding. The round was led by CICC with participation from Qianhai Ark, Liando Group, Yuanhe Capital, HeFangTian Venture Partnership and existing investors Sherpa Healthcare Partners, Decheng Capital and Matrix Partners China. The company intends to use the funds to support its Tumor-Infiltrating […] The post Grit Biotechnology Closes $60M Series B Financing appeared first on FinSMEs.VintaBio Emerges Out of Stealth with $64 Million Funding and a CEO
VintaBio, a contract development and manufacturing organization specializing in life sciences, emerged out of stealth on Tuesday and said it... Read More The post VintaBio Emerges Out of Stealth with $64 Million Funding and a CEO appeared first on citybiz.CG Oncology Raises $120M in Series E Financing
CG Oncology, an Irvine, CA-based oncolytic immunotherapy company, raised $120M in Series E funding. The round was co-led by ORI Capital, Longitude Capital and Decheng Capital, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group and Sirona Capital. In connection with the financing, Brian Liu, M.D., Principal from Longitude Capital, will join […] The post CG Oncology Raises $120M in Series E Financing appeared first on FinSMEs.
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Decheng Capital
Sign Up For FreeTo access detailed company insights
Decheng Capital is a global investment firm established in 2012, specializing in providing capital and strategic support to early-stage life science companies and growth stage healthcare companies. With over $2.1 billion in capital, the firm aims to build legendary companies by leveraging revolutionary technologies and strong market presence. Deche... Read More
